A Leading Location
The German capital region provides outstanding potential for development and ideal conditions for the biotechnology and pharmaceuticals industry. Its major strengths are a unique research landscape and a close network of the players along the entire value-added chain. Its many technology parks and networks in various fields of modern biotechnology provide an excellent infrastructure and form the technological backbone of the biotechnology and pharmaceuticals industry in Berlin and Brandenburg.
Are you planning on developing your company’s presence in the German capital? A good choice! We will help you implement your decision to locate or expand your company in Berlin-Brandenburg.
Submission deadline for abstracts to be considered for oral presentation will be 31 May 2017. Abstract submission deadline for poster presentations will be 20 July 2017.
Eckert & Ziegler 2016 annual financial statements: Sales and profit according to plan. Gross profit margin up by 6%. Change in the Supervisory Board
Eckert & Ziegler Strahlen- und Medizintechnik AG, a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, reported sales of € 138.0 million (prior year: € 140.0 million) in...
The European Research Council (ERC) is celebrating its 10th anniversary this week. Some 14 researchers at the Max Delbrück Center for Molecular Medicine have benefited so far from its funding – in some cases more than once.
Anaerobic digestion is a complex process of subsequent and interacting degradation steps. A precise control of this complex biological process is crucial to make the biogas production process more efficient, reliable and...
What is critical when designing Clinical Trials? How are relevant endpoints chosen?